Abstract: Disclosed is a composition for anti-aging or skin regeneration comprising Isoprocurcumenol, and use of Isoprocurcumenol or a salt thereof and, more particularly, to a composition for anti-aging or skin regeneration comprising Isoprocurcumenol represented by the following formula (1) or a salt thereof, and use of Isoprocurcumenol or a salt thereof.

Abstract: Disclosed is a composition for anti-aging or skin regeneration comprising Okanin, and use of Okanin or a salt thereof and, more particularly, to a composition for anti-aging or skin regeneration comprising Okanin represented by the following formula (1) or a salt thereof, and use of Okanin or a salt thereof.

Abstract: The present invention relates to a pharmaceutical composition comprising piperonylic acid as an effective ingredient for anti-aging or regenerating the skin. A composition according to the present invention utilizes piperonylic acid that various plant species naturally contain therein and thus does not cause side effects. Piperonylic acid activates signals associated with cell survival, growth, and proliferation to exhibit the effect of increasing the resistance and survival of skin cells against external stimuli and enhancing the regeneration of the skin damaged due to external stimuli or senescence. In addition, piperonylic acid of the present invention has a similar function to EGF, but is stable and small in size in contrast to EGF. Thus, piperonylic acid of the present invention has the advantage of being able to easily move to the skin basal layer across the skin barrier and perform its function.

Abstract: The present invention relates to a composition comprising gossypetin or a salt thereof for prevention or treatment of neurodegenerative disease. Having an excellent prophylactic and therapeutic effect on neurodegenerative disease and excellently improving memory and cognitive functions, the composition of the invention can be advantageously used not only for preventing and treating neurodegenerative disease, but also for improving memory and cognitive function.

Abstract: The present invention relates to a pharmaceutical composition comprising piperonylic acid as an effective ingredient for anti-aging or regenerating the skin. A composition according to the present invention utilizes piperonylic acid that various plant species naturally contain therein and thus does not cause side effects. Piperonylic acid activates signals associated with cell survival, growth, and proliferation to exhibit the effect of increasing the resistance and survival of skin cells against external stimuli and enhancing the regeneration of the skin damaged due to external stimuli or senescence. In addition, piperonylic acid of the present invention has a similar function to EGF, but is stable and small in size in contrast to EGF. Thus, piperonylic acid of the present invention has the advantage of being able to easily move to the skin basal layer across the skin barrier and perform its function.

Abstract: The present invention relates to a pharmaceutical composition for preventing or treating obesity, comprising cyclo-hispro as an active ingredient. Specifically, the present invention has the effect of reducing body weight and body mass, and further improving leptin resistance. In addition, the present invention relates to a pharmaceutical composition for preventing or treating obesity, characterized in that the pharmaceutical composition comprises cyclo-hispro and zinc and is administered once a day.

Abstract: The present invention relates to a composition for improving skin whitening or thermal aging comprising 8-methoxybutin or an acceptable salt thereof as an active ingredient. The composition has no cytotoxicity, increases the expression of heat shock protein 70 (HSP70)—to prevent thermal aging, and inhibits the melanogenesis by decreasing level of tyrosinase gene expression involved in skin pigmentation. Therefore, the composition including 8-methoxybutin or an acceptable salt thereof as an active ingredient can be effectively used as a cosmetic composition, dermatologic agent, health functional food, and the like for improving skin whitening or thermal aging.

Abstract: The present invention relates to a pharmaceutical composition comprising piperonylic acid as an effective ingredient for anti-aging or regenerating the skin. A composition according to the present invention utilizes piperonylic acid that various plant species naturally contain therein and thus does not cause side effects. Piperonylic acid activates signals associated with cell survival, growth, and proliferation to exhibit the effect of increasing the resistance and survival of skin cells against external stimuli and enhancing the regeneration of the skin damaged due to external stimuli or senescence. In addition, piperonylic acid of the present invention has a similar function to EGF, but is stable and small in size in contrast to EGF. Thus, piperonylic acid of the present invention has the advantage of being able to easily move to the skin basal layer across the skin barrier and perform its function.

Abstract: The present invention relates to a pharmaceutical formulation for preventing or treating diabetes mellitus, comprising cyclo-hispro as an active ingredient. Specifically, the present invention has the effect of lowering the concentration of glycated hemoglobin (HbA1c) in the blood, and further improving leptin resistance. In addition, the present invention relates to a pharmaceutical formulation for preventing or treating diabetes mellitus, characterized in that the pharmaceutical formulation comprises cyclo-hispro and zinc and is administered once a day.

Abstract: The present invention relates to a pharmaceutical composition for preventing or treating diabetes, and controlling a side effect from peroxisome proliferator-activated receptor-gamma (PPAR-gamma) activation, wherein the pharmaceutical composition comprises (a) an amodiaquine compound or a pharmaceutically acceptable salt thereof and (b) an antidiabetic drug as active ingredients. Specifically, the composition prevents or treats simultaneously one or more selected from the group consisting of type 2 diabetes reactive to PPAR-gamma activation, and obesity, dyslipidemia, cardiovascular diseases, and fatty cirrhosis reactive to peroxisome proliferator-activated receptor-alpha (PPAR-alpha) activation.

Abstract: The present invention relates to a pharmaceutical composition for preventing or treating diabetes, and controlling a side effect from peroxisome proliferator-activated receptor-gamma (PPAR-gamma) activation, wherein the pharmaceutical composition comprises (a) an amodiaquine compound or a pharmaceutically acceptable salt thereof and (b) an antidiabetic drug as active ingredients. Specifically, the composition prevents or treats simultaneously one or more selected from the group consisting of type 2 diabetes reactive to PPAR-gamma activation, and obesity, dyslipidemia, cardiovascular diseases, and fatty cirrhosis reactive to peroxisome proliferator-activated receptor-alpha (PPAR-alpha) activation.

Abstract: The present invention relates to a novel use of a composition containing, as an active ingredient, an amodiaquine compound or a pharmaceutically acceptable salt thereof and specifically, to a metabolic disease prevention, alleviation or treatment use of a composition containing, as an active ingredient, an amodiaquine compound or a pharmaceutically acceptable salt thereof, the composition activating both peroxisome proliferator-activated receptor-gamma (PPAR-?) and peroxisome proliferator-activated receptor-alpha (PPAR-?).

Abstract: The present invention relates to a novel use of a composition containing, as an active ingredient, an amodiaquine compound or a pharmaceutically acceptable salt thereof and specifically, to a metabolic disease prevention, alleviation or treatment use of a composition containing, as an active ingredient, an amodiaquine compound or a pharmaceutically acceptable salt thereof, the composition activating both peroxisome proliferator-activated receptor-gamma (PPAR-?) and peroxisome proliferator-activated receptor-alpha (PPAR-?).

Abstract: Provided is a composition containing myricetin or a pharmaceutically available salt thereof as an active ingredient. The composition increases exercise capacity and enhances physical strength. In addition, the composition prevents aging and recovers from fatigue. The composition increases energy efficiency by improving the function of mitochondria, and also has an antiobesity effect by increasing energy consumption. Therefore, the composition may be significantly applied in a functional food or medicine field.

Abstract: Provided is a composition containing myricetin or a pharmaceutically available salt thereof as an active ingredient. The composition increases exercise capacity and enhances physical strength. In addition, the composition prevents aging and recovers from fatigue. The composition increases energy efficiency by improving the function of mitochondria, and also has an antiobesity effect by increasing energy consumption. Therefore, the composition may be significantly applied in a functional food or medicine field.

Abstract: The present invention relates to a method of screening for modulator of chaperonin that is involved in protein aggregation inducing neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease and Huntington's disease, use of the chaperonin modulator screened by the method for prevention and treatment of neurodegenerative diseases. According to the present invention, novel negative chaperonin modulator is provided, and chaperonin modulator may be more rapidly and conveniently screened with the negative modulator as a target. Furthermore, by using the screened material, neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease and Huntington's disease may be effectively prevented or treated without concern for cell death due to autophagy, which is the existing method of removing protein aggregate.

Abstract: The present invention relates to a method of screening for modulator of chaperonin that is involved in protein aggregation inducing neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease and Huntington's disease, use of the chaperonin modulator screened by the method for prevention and treatment of neurodegenerative diseases. According to the present invention, novel negative chaperonin modulator is provided, and chaperonin modulator may be more rapidly and conveniently screened with the negative modulator as a target. Furthermore, by using the screened material, neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease and Huntington's disease may be effectively prevented or treated without concern for cell death due to autophagy, which is the existing method of removing protein aggregate.

Abstract: Provided is a composition containing myricetin or a pharmaceutically available salt thereof as an active ingredient. The composition increases exercise capacity and enhances physical strength. In addition, the composition prevents aging and recovers from fatigue. The composition increases energy efficiency by improving the function of mitochondria, and also has an antiobesity effect by increasing energy consumption. Therefore, the composition may be significantly applied in a functional food or medicine field.

Abstract: The present invention relates to a method of screening for modulator of chaperonin that is involved in protein aggregation inducing neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease and Huntington's disease, use of the chaperonin modulator screened by the method for prevention and treatment of neurodegenerative diseases. According to the present invention, novel negative chaperonin modulator is provided, and chaperonin modulator may be more rapidly and conveniently screened with the negative modulator as a target. Furthermore, by using the screened material, neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease and Huntington's disease may be effectively prevented or treated without concern for cell death due to autophagy, which is the existing method of removing protein aggregate.

Abstract: Provided is a coagulation apparatus using cold plasma. In the coagulation apparatus, the cold plasma is generated by a microwave resonator with low power consumption in the atmosphere, and the cold plasma is vented on a bleeding portion of a wound. Accordingly, it is possible to accelerate coagulation process, to reduce unfavorable side effect such as burns on the wound, and to efficiently sterilize the wound, simultaneously. In addition, it is possible to implement a small-sized portable coagulation apparatus.